When a Referral Is Not Enough: Finding a Qualified Medical Device Distributor

Signals to watch

• distributor selection operates on reputation
• not verification
• one referral chain compounds six unverified claims
• evidence review breaks the cycle before onboarding

Composite industry case. This page describes a reusable operating problem and decision method. It does not represent a named customer, real conversation, contract, revenue result or testimonial.

The Workday That Reveals the Real Problem

You have spent three weeks preparing a market entry timeline. Registration files sit in a folder. The logistics partner is confirmed. Hospital tenders are mapped. Then the question arrives from your steering group: Who is the in-country distributor?

A colleague recommends a name. Another team member has “heard good things.” Someone forwards a contact card from last year’s trade show. Within an hour, a referral chain has produced a candidate — but nobody in the room can answer six basic questions:

• Who holds the legal registration for this device category in that country?
• Which hospital groups does this distributor currently have active access agreements with?
• What is their complaint-handling process under local vigilance requirements?
• How do they manage sterile inventory traceability batch by batch?
• What service engineer coverage exists outside the capital city?
• Who owns the license renewals — the manufacturer or the distributor?

Not one of these answers lives inside a referral. Yet the team is one conversation away from moving forward.

Why Teams Misread the Referral Shortcut

Referral-based distributor selection feels efficient because it compresses a screening step into a conversation. The problem is structural: a referral transfers confidence in one dimension — typically relationship strength or perceived market footprint — but a distributor’s capability lives in at least six independent domains. A strong sales team does not guarantee complaint-handling compliance. A long operating history does not guarantee current hospital access credentials.

The compound effect is invisible. A chain of three referrals (a colleague recommending a person who recommends a company that references a partner) passes along unverified claims about unverified claims. By the time the name reaches your desk, the original referrer’s confidence has been diluted across six domains they never evaluated. The team treats the recommendation as a signal; in reality, it is noise multiplied by relationships.

An Evidence Review Framework for Distributor Qualification

Before any onboarding decision, build a review that treats each operational domain as its own evidence thread. The method has five steps and fits inside a two-week window — no software required.

Step 1 — Decompose the role into six evidence domains. Write them down: registration ownership, license management, hospital access agreements, sterile inventory and logistics, service and field coverage, complaint and vigilance handling. Each domain is binary at first pass: can the distributor produce any documentary evidence for it, yes or no?

Step 2 — Assign one evidence owner per domain. This is not a single person doing all the checking. The regulatory affairs contact owns registration verification. The service lead confirms engineer coverage. The supply chain contact reviews inventory protocols. Owners produce one piece of verifiable evidence each — a valid registration number, a signed hospital access agreement, a complaint log excerpt, a service call record, a batch trace report.

Step 3 — Set a decision window, not an open investigation. Choose a calendar date by which all six pieces of evidence must arrive. Without a deadline, the review drifts into indefinite due diligence. The window signals seriousness to the distributor and forces the team to decide with the evidence available.

Step 4 — Hold a review session where each owner presents one finding. The session has one output: a documented action per domain. Each action has an owner, a piece of evidence that produced it, and a next step — accept, request clarification, or reject. No action, no distributor move.

Step 5 — Write the composite picture. A distributor passes on four of six domains and is unclear on two. That is not a failure — it is a decision with visible edges. The team can proceed with conditions on the unclear domains or pause to seek alternatives. The composite is useful precisely because it reveals trade-offs that a single referral would have smoothed over.

Your Next Step: Run a Zero-Software Pilot This Week

Pick one market you are evaluating. Decompose the distributor role into the six domains. Assign owners from your existing team — even if they hold other roles. Set a fourteen-day evidence deadline. Hold a thirty-minute review session. Produce one action per domain.

The output will be a single document: six actions, each with an owner, the evidence seen, and a go/no-go/go-with-conditions verdict. That document is the review artifact that referrals never provide. It is also the foundation for every future market-entry decision, because the evidence owners and the domain structure are reusable regardless of the country or product category.

What Automation Cannot Replace

Evidence collection scales with process discipline, not with tools. No software can decide whether a complaint log excerpt with three entries over twelve months is thin or adequate for a specific device risk class — that is a human judgment call that depends on market context, device type, and the team’s risk tolerance.

What automation does best here is signal discovery — surfacing public registration data, license expiry alerts, or hospital network changes that a human reviewer would not check daily. And it handles evidence organization: keeping the six domains visible, tracking what has arrived and what is missing, and flagging when a decision window is approaching.

But the review itself — the session where an owner says “this evidence is sufficient” or “this is not enough” — remains a human conversation. That is by design. The method works because it replaces the single referral with six accountable judgments, each backed by something the team can see and debate. That composite judgment is the one thing a market entry cannot outsource.

Build the review structure first. The automation finds its place around it.

Frequently asked questions

Why is a referral insufficient for distributor qualification?

A referral transfers trust in one dimension — usually sales footprint — but a distributor must also hold valid registrations, manage sterile inventory, handle complaints, and maintain hospital access credentials. Referrals rarely verify these six distinct obligations.

How many evidence sources should a review include before onboarding a distributor?

Plan for at least six — one per operational domain. Fewer than four leaves the same gaps a single referral would have introduced.

What cannot be automated in distributor qualification?

The judgment call that reconciles conflicting evidence — for example, strong hospital access paired with weak complaint-handling documentation. Only a human reviewer can weigh whether that trade-off is acceptable for a specific market and product category.